A-RAF Antibody (YA2673)

A-Raf (ARAF) is a member of the RAF serine/threonine kinase family and functions as a downstream effector of RAS that initiates signaling through the RAF-MEK-ERK mitogen-activated protein kinase (MAPK) cascade, thereby regulating cellular growth, proliferation, and differentiation^[1][2]. Mechanistically, activated A-Raf phosphorylates MEK1/2 and contributes to ERK activation, placing ARAF at a critical upstream position in MAPK pathway regulation^[1][2]. Dysregulation of the RAS-RAF-MEK-ERK signaling network is strongly associated with oncogenesis, and recurrent activating alterations in ARAF have been identified in multiple cancer types, supporting its relevance in tumor biology and experimental cancer models^[3][4]. Compared with the related RAF isoforms BRAF and CRAF, A-Raf displays distinct biochemical properties, including substantially lower kinase activity toward MEK and tighter regulatory control, which may contribute to isoform-specific signaling outputs and biological functions^[3][2]. This distinction is particularly important because oncogenic activation mechanisms differ among RAF family members, and mutations equivalent to highly transforming BRAF variants do not necessarily produce the same biological effects in ARAF^[2]. In disease models, ARAF dimerization has been shown to promote MAPK pathway activation and tumor cell invasion, highlighting its functional contribution beyond its comparatively weak catalytic activity^[4]. For experimental and therapeutic applications, RAF inhibitors remain important tools for interrogating ARAF-dependent signaling; however, several type II RAF inhibitors exhibit reduced potency against A-Raf relative to other RAF isoforms, emphasizing the need to consider isoform selectivity when designing mechanistic studies or targeted therapeutic strategies^[1][5].